ArticleBiotechnology journal2026
Analytical Centrifugal Ultrafiltration as a Tool for High Throughput Process Development in Virus Removal Filtration.
Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Virus removal filtration constitutes an essential component in biopharmaceutical manufacturing processes for both recombinant and plasma-derived protein products. The increasing demand for protein-based therapies necessitates expedited analytical screening methodologies for virus filtration materials and process parameters utilizing high-throughput development (HTPD) platforms. This study examines a novel HTPD methodology, specifically the implementation of analytical centrifugal ultrafiltration, as a scaled-down virus removal filtration tool. A nanocellulose-derived filter membrane of controlled porosity (33 µm thickness, 23 nm) was integrated into a centrifugal ultrafiltration apparatus. The system underwent comprehensive evaluation to determine centrifugal ultrafiltration flux characteristics, product yield across varying buffer viscosities, virus removal capacity utilizing model MS2 (27 nm) and ΦX174 (28 nm) bacteriophages, and IgG throughput capacity. Application of centrifugal force facilitated the generation of multiple filtration pressure gradients suitable for small-volume sample processing. The resultant flux decay profiles exhibited high reproducibility, demonstrating superior IgG throughput and virus removal efficiency. Overall, the approach adds value to the arsenal of analytical tools useful for HTPD in biopharmaceutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.